CalciMedica (NASDAQ:CALC – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14, Zacks reports.
CalciMedica Stock Up 4.0 %
Shares of CALC opened at $2.07 on Friday. The stock has a market cap of $27.91 million, a price-to-earnings ratio of -1.92 and a beta of 1.20. CalciMedica has a 12 month low of $1.83 and a 12 month high of $6.27. The company has a 50-day moving average price of $2.41 and a two-hundred day moving average price of $3.19.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of CalciMedica in a research note on Tuesday, March 4th.
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- The Most Important Warren Buffett Stock for Investors: His Own
- Microsoft’s Big Malaysia Bet Could Pay Off for Investors
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- The 5 Most Oversold Stocks on the Market Are…
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Archer Aviation Stock Sees Surge in Institutional Buys
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
